Sei Investments Co. Sells 41,390 Shares of IDEXX Laboratories, Inc. $IDXX

Sei Investments Co. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 30.5% in the first quarter, HoldingsChannel.com reports. The fund owned 94,486 shares of the company’s stock after selling 41,390 shares during the quarter. Sei Investments Co.’s holdings in IDEXX Laboratories were worth $53,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. Elyxium Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. State Street Corp grew its position in IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after buying an additional 138,956 shares in the last quarter. J. Stern & Co. LLP increased its position in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Geode Capital Management LLC raised its position in shares of IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. raised its position in IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after purchasing an additional 181,955 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.9%

IDXX stock opened at $544.32 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The firm has a market capitalization of $42.94 billion, a PE ratio of 40.08, a PEG ratio of 2.98 and a beta of 1.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a 50-day simple moving average of $556.27 and a two-hundred day simple moving average of $595.41.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm posted $2.91 EPS. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.